Vera Therapeutics VERA Accretion Of Loan Exit Fee And Amortization Of Loan Costs
Accretion Of Loan Exit Fee And Amortization Of Loan Costs at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept vera:AccretionOfLoanExitFeeAndAmortizationOfLoanCosts.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's accretion of loan exit fee and amortization of loan costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's accretion of loan exit fee and amortization of loan costs?
- Vera Therapeutics (VERA) reported accretion of loan exit fee and amortization of loan costs of $639K in Q1 2026.
- How has Vera Therapeutics's accretion of loan exit fee and amortization of loan costs changed year-over-year?
- Vera Therapeutics's accretion of loan exit fee and amortization of loan costs increased by 189.1% year-over-year, from $221K to $639K.
- What does accretion of loan exit fee and amortization of loan costs mean?
- This represents the non-cash expense related to the amortization of loan-related costs and the accretion of exit fees associated with debt financing arrangements. It reflects the systematic recognition of borrowing costs over the life of the loan agreement. Investors monitor this to understand the true effective cost of debt beyond stated interest payments.